PHARMACOECONOMIC ISSUES OF ADALIMUMAB THERAPY IN JUVENILE IDIOPATHIC ARTHRITIS
Background. Juvenile idiopathic arthritis (JIA) is the most common type of arthritis in children and is associated with reduced quality of life and increased health care costs. Objective. To evaluate the cost effectiveness of the tumour necrosis factor inhibitor adalimumab (ADA) vs. non-biologic the...
| Autori principali: | , , , |
|---|---|
| Natura: | Articolo |
| Lingua: | Russian |
| Pubblicazione: |
Union of pediatricians of Russia
2012-08-01
|
| Serie: | Педиатрическая фармакология |
| Soggetti: | |
| Accesso online: | https://www.pedpharma.ru/jour/article/view/302 |